Alpha 2.0
Login Register
» Articles » PMID: 32403946

Coronavirus Disease-2019 in Cancer Patients. A Report of the First 25 Cancer Patients in a Western Country (Italy)

Overview
Journal Future Oncol
Specialty Oncology
Date 2020 May 15
PMID 32403946
Citations 55
Authors
Elisa Maria Stroppa
Ilaria Toscani
Chiara Citterio
Elisa Anselmi
Elena Zaffignani
Mauro Codeluppi
Luigi Cavanna
Affiliations
Soon will be listed here.
Abstract

We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). 25 cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. 20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.

Citing Articles

Antibody Response Following COVID-19 Vaccination in Malaysian Cancer Patients and Healthy Individuals.

Song C, Ahmad Bustamam R, Gin Gin G, Saad M, Abdul Satar N, Ramasamy A Cureus. 2024; 16(11):e73528.

PMID: 39669806 PMC: 11636583. DOI: 10.7759/cureus.73528.

Exploring hematic crasis variations in cancer patients following SARS-CoV-2 vaccination: a real-practice study.

Montella L, DellAversana C, Pacella D, Troise S, Russo P, Cacciapuoti V Infect Agent Cancer. 2023; 18(1):62.

PMID: 37848958 PMC: 10583381. DOI: 10.1186/s13027-023-00532-9.

Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.

Wu M, Liu S, Wang C, Wu Y, Liu J PLoS One. 2023; 18(9):e0291178.

PMID: 37682957 PMC: 10490932. DOI: 10.1371/journal.pone.0291178.

Safeguarding COVID-19 and cancer management: drug design and therapeutic approach.

Thorat N, Pricl S, Parchur A, Somvanshi S, Li Q, Umrao S Open Res Eur. 2023; 1:77.

PMID: 37645153 PMC: 10445946. DOI: 10.12688/openreseurope.13841.1.

Characteristics and Outcomes of COVID-19 Cancer Patients Admitted to a Portuguese Intensive Care Unit: A Case-Control Study.

Ranchor R, Pereira N, Medeiros A, Magalhaes M, Marinho A, Araujo A Cancers (Basel). 2023; 15(12).

PMID: 37370874 PMC: 10296675. DOI: 10.3390/cancers15123264.

References
1.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View
2.
Silverstein W, Stroud L, Cleghorn G, Allen Leis J . First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia. Lancet. 2020; 395(10225):734. PMC: 7134552. DOI: 10.1016/S0140-6736(20)30370-6. View
3.
Sica A, Massarotti M . Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017; 85:117-125. DOI: 10.1016/j.jaut.2017.07.010. View
4.
Bersanelli M . Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020; 12(5):269-273. PMC: 7117596. DOI: 10.2217/imt-2020-0067. View
5.
Longbottom E, Torrance H, Owen H, Fragkou P, Hinds C, Pearse R . Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways. Ann Surg. 2015; 264(2):370-7. DOI: 10.1097/SLA.0000000000001484. View